Search All News
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
- September 28, 2012
CUMC's Dr. Megan Sykes talks to "The Takeaway" about mouse stand-ins leading the way towards cures, treatment for patients.
Source:The New York TimesSeptember 26, 2012
Megan Sykes, a medical researcher at Columbia, has a mouse with a human immune system — her own. She calls it “Mini-Me.”
- September 20, 2012
Columbia University Medical Center (CUMC) is one of 50 institutions selected nationwide from more than 700 applications for a “Provocative Questions” grant from the National Cancer Institute (NCI).
- September 5, 2012
David Brenner, PhD, DSc, discusses three aspects of radiation and CT scans—quality control, training, and overuse—that urgently need addressing.
- July 30, 2012
A common & aggressive brain cancer appears to be caused by a genetic mutation -- and targeting it with a drug showed promise in mice.
- July 26, 2012
Some cases of glioblastoma, the most common & aggressive form of brain cancer, are caused by the fusion of 2 adjacent genes.
- June 4, 2012
With this new gift, Mr. and Mrs. Irving have generously committed nearly $200 million to CUMC and its partner, NewYork-Presbyterian Hospital/Columbia.
- May 22, 2012